Published on
Monday, August 18, 2008
Two laws recently enacted in
Massachusetts reflect the contradictory attitudes of the state’s political
leaders toward life sciences companies. According to the drug industry, whether
the state will remain a good place for one of the world’s largest biopharmaceutical
clusters will depend on how one of the new laws is put into practice.
On the plus side, the Life
Sciences Initiative (LSI), signed into law on June 16, could pump $1 billion
into the state’s biomedical community over a decade through grants, loans and
tax breaks.